NPS+ (EU5) [Asthma/COPD]
Is there a loyalty issue for the leading asthma/COPD brands in Europe?
With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do physicians really think about the leading brands? And are they talking positively or negatively about each to their peers?
Brand marketers can find out everything they need to know about how their brand is being perceived in NPS+ Asthma/COPD (EU5).
This report reveals satisfaction levels, message association for key brands and how well each brand is faring in the loyalty stakes. It also shows at a glance how well a brand compares to 10 other European asthma and COPD competitors, providing crucial evidence for drug marketing strategies.
Interested in the US market? Click here to see the US Edition.
Insight into 11 Leading Asthma/COPD Treatments
NPS+ Asthma/COPD (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing asthma/COPD drugs. You’ll discover:
We surveyed 150 Pulmonologists and General Practitioners across the EU (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.
We conducted the survey between 3rd and 6th of April 2017.
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
'How likely are you to recommend this brand to a colleague?'
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
How is NPS calculated?
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
ABOUT FIRSTWORD
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
With so many mono and combination therapies on offer to treat asthma and COPD, how is an abundance of choice impacting brand loyalty? What do physicians really think about the leading brands? And are they talking positively or negatively about each to their peers?
Brand marketers can find out everything they need to know about how their brand is being perceived in NPS+ Asthma/COPD (EU5).
This report reveals satisfaction levels, message association for key brands and how well each brand is faring in the loyalty stakes. It also shows at a glance how well a brand compares to 10 other European asthma and COPD competitors, providing crucial evidence for drug marketing strategies.
Interested in the US market? Click here to see the US Edition.
Insight into 11 Leading Asthma/COPD Treatments
- Anoro (umeclidinium/vilanterol; GSK)
- Daxas (roflumilast; AstraZeneca)
- Eklira (aclidinium; AstraZeneca)
- Onbrez (indacaterol; Novartis)
- Relvar Ellipta (vilanterol/fluticasone furoate; GSK)
- Seebri (glycopyrronium; Novartis)
- Seretide (fluticasone/salmeterol; GSK)
- Spiriva (tiotropium; Boehringer)
- Symbicort (budesonide/formoterol; AstraZeneca)
- Ultibro (indacaterol/glycopyrronium; Novartis)
- Xolair (omalizumab; Novartis/Roche)
- Brand loyalty is hard won: Numerous choices mean that brand preference is proving difficult to secure exclusively for asthma/COPD drugs. How do individual brands compare?
- Satisfaction with drug choice is high: With low loyalty for specific brands, could marketers do more to help theirs stand out from the crowd?
- Competition is fierce: Promoters of individual brands are also promoting up to 6 others. How much share of the Promoter pool has your brand secured, and can more be achieved?
- Some favourites: European Promoters of the brands covered in this report claim to promote 6 of the 10 drugs included in this survey. Which ones are winners and which ones are losers?
- Which brands do Detractors choose? Those who are not fans of certain brands are still favouring others. See which brands lose out and which gain.
NPS+ Asthma/COPD (EU5) offers valuable insight into brand loyalty from the perspective of those currently prescribing asthma/COPD drugs. You’ll discover:
- Exactly how satisfied the European market is.
- How loyal doctors are to your brand.
- How many other brands your Promoters recommend.
- Which other brands your Promoters and Detractors recommend.
- How much market share your brand has among Promoters and Detractors.
- How much more of a brand Promoters prescribe than Detractors
- Which messages Promoters, Passives and Detractors associate with your brand.
- Your brand DNA: what doctors really think of your brand—in their own words.
We surveyed 150 Pulmonologists and General Practitioners across the EU (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.
We conducted the survey between 3rd and 6th of April 2017.
What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
'How likely are you to recommend this brand to a colleague?'
Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:
- Detractors are those who answer 0 – 6.
- Passives are those who answer 7 – 8.
- Promoters are those who answer 9 - 10.
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
How is NPS calculated?
- The percentage of detractors - the percentage of promoters = NPS.
NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
ABOUT FIRSTWORD
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. CHART 1: NET PROMOTER SCORE?
2. CHART 2: HOW LOYAL ARE DOCTORS TO MY BRAND?
3. CHART 3: HOW SATISFIED IS THE MARKET?
4. CHART 4: HOW MANY OTHER BRANDS ARE PROMOTED BY MY PROMOTERS?
5. CHART 5: WHICH OTHER BRAND IS MOST PROMOTED BY MY PROMOTERS?
6. CHART 6: WHICH OTHER BRANDS ARE PROMOTED BY MY DETRACTORS?
7. CHART 7: WHAT IS MY BRAND'S MARKET SHARE AMONG PROMOTERS AND DETRACTORS?
8. CHART 8: WHAT BRAND MESSAGES ARE ASSOCIATED WITH PROMOTERS, PASSIVES AND DETRACTORS (BY
9. BRAND)?
10. CHART 9: WHAT DOES MY BRAND REPRESENT TO PROMOTERS AND DETRACTORS (BY BRAND)?
11. APPENDIX
2. CHART 2: HOW LOYAL ARE DOCTORS TO MY BRAND?
3. CHART 3: HOW SATISFIED IS THE MARKET?
4. CHART 4: HOW MANY OTHER BRANDS ARE PROMOTED BY MY PROMOTERS?
5. CHART 5: WHICH OTHER BRAND IS MOST PROMOTED BY MY PROMOTERS?
6. CHART 6: WHICH OTHER BRANDS ARE PROMOTED BY MY DETRACTORS?
7. CHART 7: WHAT IS MY BRAND'S MARKET SHARE AMONG PROMOTERS AND DETRACTORS?
8. CHART 8: WHAT BRAND MESSAGES ARE ASSOCIATED WITH PROMOTERS, PASSIVES AND DETRACTORS (BY
9. BRAND)?
10. CHART 9: WHAT DOES MY BRAND REPRESENT TO PROMOTERS AND DETRACTORS (BY BRAND)?
11. APPENDIX
